Tarjinder Singh

Tarjinder Singh

Auto-generated profile, based on publicly available information

Tarjinder Singh

New York Genome Center, New York, NY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2014 in Nature
Verified
Journal Article
Open access
PDF file
SRSilvia De Rubeis
Silvia De Rubeis
XHXin He
Xin He
AGArthur P. Goldberg
Arthur P. Goldberg
CPChristopher S. Poultney
Christopher S. Poultney
KSKaitlin Samocha
Kaitlin Samocha
JBJoseph D. Buxbaum
Joseph D. Buxbaum
The genetic architecture of autism spectrum disorder involves the interplay of common and rare variants and their impact on hundreds of genes. Using exome sequencing, here we show that analysis of rare coding variation in 3,871 autism cases and 9,937 ancestry-matched or parental controls implicates 22 autosomal genes at a false discovery rate (FDR) < 0.05, plus a set of 107 autosomal genes strongly enriched for those likely to affect risk (FDR < 0.30). These 107 genes, which show unusual evolutionary constraint against mutations, incur de novo loss-of-function mutations in over 5% of autistic subjects. Many of the genes implicated encode proteins for synaptic formation, transcriptional regulation and chromatin-remodelling pathways. These include voltage-gated ion channels regulating the propagation of action potentials, pacemaking and excitability–transcription coupling, as well as histone-modifying enzymes and chromatin remodellers—most prominently those that mediate post-translational lysine methylation/demethylation modifications of histones.

8 April 2022 in Nature
Verified
Journal Article
Closed access
PDF file
TSTarjinder Singh
Tarjinder Singh
TPTimothy Poterba
Timothy Poterba
DCDavid Curtis
David Curtis
HAHuda Akil
Huda Akil
MEMariam Al Eissa
Mariam Al Eissa
MDMark J. Daly
Mark J. Daly

14 March 2016 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
TSTarjinder Singh
Tarjinder Singh
MKMitja I Kurki
Mitja I Kurki
DCDavid Curtis
David Curtis
SPShaun M Purcell
Shaun M Purcell
LCLucy Crooks
Lucy Crooks
JBJeffrey C Barrett
Jeffrey C Barrett

1 August 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASAlejandro Sifrim
Alejandro Sifrim
MHMarc-Phillip Hitz
Marc-Phillip Hitz
AWAnna Wilsdon
Anna Wilsdon
JBJeroen Breckpot
Jeroen Breckpot
STSaeed H Al Turki
Saeed H Al Turki
MHMatthew E Hurles
Matthew E Hurles
Matthew Hurles and colleagues report exome sequencing of 1,891 individuals with syndromic or nonsyndromic congenital heart defects (CHD). They found that nonsyndromic CHD patients were enriched for protein-truncating variants in CHD-associated genes inherited from unaffected parents and identified three new syndromic CHD disorders caused by de novo mutations. Congenital heart defects (CHDs) have a neonatal incidence of 0.8–1% (refs. 1,2). Despite abundant examples of monogenic CHD in humans and mice, CHD has a low absolute sibling recurrence risk (∼2.7%)3, suggesting a considerable role for de novo mutations (DNMs) and/or incomplete penetrance4,5. De novo protein-truncating variants (PTVs) have been shown to be enriched among the 10% of 'syndromic' patients with extra-cardiac manifestations6,7. We exome sequenced 1,891 probands, including both syndromic CHD (S-CHD, n = 610) and nonsyndromic CHD (NS-CHD, n = 1,281). In S-CHD, we confirmed a significant enrichment of de novo PTVs but not inherited PTVs in known CHD-associated genes, consistent with recent findings8. Conversely, in NS-CHD we observed significant enrichment of PTVs inherited from unaffected parents in CHD-associated genes. We identified three genome-wide significant S-CHD disorders caused by DNMs in CHD4, CDK13 and PRKD1. Our study finds evidence for distinct genetic architectures underlying the low sibling recurrence risk in S-CHD and NS-CHD.

1 February 2014 in Cell Metabolism
Verified
Journal Article
Closed access
TGTao Gao
Tao Gao
BMBrian McKenna
Brian McKenna
CLChanghong Li
Changhong Li
MRMaximilian Reichert
Maximilian Reichert
JNJames Nguyen
James Nguyen
BSBen Z. Stanger
Ben Z. Stanger

20 September 2022 in Nature Aging
Verified
Journal Article
Open access
PDF file
BDBorislav Dejanovic
Borislav Dejanovic
TWTiffany Wu
Tiffany Wu
MTMing-Chi Tsai
Ming-Chi Tsai
DGDavid Graykowski
David Graykowski
VGVineela D. Gandham
Vineela D. Gandham
JHJesse E. Hanson
Jesse E. Hanson
Microglia and complement can mediate neurodegeneration in Alzheimer’s disease (AD). By integrative multi-omics analysis, here we show that astrocytic and microglial proteins are increased in TauP301S synapse fractions with age and in a C1q-dependent manner. In addition to microglia, we identified that astrocytes contribute substantially to synapse elimination in TauP301S hippocampi. Notably, we found relatively more excitatory synapse marker proteins in astrocytic lysosomes, whereas microglial lysosomes contained more inhibitory synapse material. C1q deletion reduced astrocyte–synapse association and decreased astrocytic and microglial synapses engulfment in TauP301S mice and rescued synapse density. Finally, in an AD mouse model that combines β-amyloid and Tau pathologies, deletion of the AD risk gene Trem2 impaired microglial phagocytosis of synapses, whereas astrocytes engulfed more inhibitory synapses around plaques. Together, our data reveal that astrocytes contact and eliminate synapses in a C1q-dependent manner and thereby contribute to pathological synapse loss and that astrocytic phagocytosis can compensate for microglial dysfunction.